Enanta Pharmaceuticals Inc News - ENTA

Empower your portfolio: Real-time discussions and actionable trading ideas.

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and...

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at...

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

alertmeipp 17 minutes ago

buying ENTA in the $5.50 range

Are you bragging?

👍️0

biotech_researcher 30 minutes ago

I violated my own covenant by buying ENTA in the $5.50 range. I normally always look at the insider ownership before I start a position. I failed to do this, and I paid the Ultimate investors choice. Insider ownership is pathetic. Most insiders own 30,000 shares or less. The CEO holds a total of 800,000 that's it. This is the latest information I have.

👍️0

vinmantoo 13 hours ago

Whether RFK is confirmed or not (I believe he and most of the nominees will be),

Given the lack of qualifications and low character, I sure hope most of the nominees are rejected.

I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.

Fully agree. I sold off half of my remaining RVNC and half of CDMO to generate a bigger cash cushion.

👍️ 1

Fred Kadiddlehopper 15 hours ago

Whether RFK is confirmed or not (I believe he and most of the nominees will be), I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.

👍️0

DewDiligence 16 hours ago

I hope that Kennedy is blocked from confirmation and I concur that it would be bullish for the biotech sector; however, I reject the notion that this is hugely consequential matter for ENTA one way or the other.

👍️ 3

biotech_researcher 18 hours ago

If Kennedy is block, this will surge. We should know relatively soon..

👍️0

InefficientMarket 18 hours ago

I added a little more today to push over 20k (excluding children) which is small potatoes compared rest of the Board. Anyone else notice that nearly every day for last two weeks the AH trades are higher than the Close. For example, i am seeing last trade at $5.23 with roughly 24,000 shares so far. Perhaps these trades are inaccurate because they are not actually AH -otherwise why would someone wait for extended trading/not use limit orders?

👍️0

alertmeipp 19 hours ago

Yes, some across the board short activities for sure. But from the few bio names I follow, none of them have 5x-6x average volumes last few weeks. That kind of volume spike is unique to ENTA.

It almost felt like they deliberately wanted to ensure we closed in the red. Every time ENTA had a run-up to breakeven during the day, a surge in volume would come in and push it down by a couple of percent.

👍️0

dewophile 20 hours ago

who the heck knows but my impression is because most bios fail and shorting across the board on average is a winning strategy some funds may do just that. In the meantime another down day (I can't remember the last time it was green) on 8x typical volume so same old same old
Maybe some folks who sold for tax reasons will buy later in the month since you have to wait a month for wash sale rules

👍️ 2

alertmeipp 20 hours ago

It actually requires a lot more conviction to hold a short position on a name that is trading less than cash value than to go long. Was thinking maybe some funds blow up, but even that won’t take this long to clear the inventory.

👍️0

dewophile 22 hours ago

it sure seems someone still wants out of a position or shorts are on the move, but it also must be the case that ENTA has become a trading name and you see the same shares changing hands multiple times a day, because otherwise it's hard to see the volume going from 100K a day to 500k+ day in day out

👍️ 3

dewophile 22 hours ago

GSK has a large respiratory and asthma business so this should be in their wheelhouse should they wish to pursue the immunology side of KIT
incidentally THRD is down 38% the last 2 trading days. I know bios have been pressured but this seems extreme. They are due to present phase 1 healthy volunteer data (along w biomarker data) this quarter. I see no news

👍️ 1

DewDiligence 1 day ago

Thanks. I may have stretched by pigeonholing the GSK deal as immunology, but it does bring the potential for GSK to expand into KIT immunology, as you noted.

👍️0

dewophile 1 day ago

GSK is in oncology but it is targeted to KIT and like BPMC they could segue to cKIT immunology down the road
GSK oncology after a terrible start has been a bit of a bright spot for the company. I sold most of my shares but still have a small position

👍️0

DewDiligence 1 day ago

Recent Immunology Deals Pertinent to ENTA (for_yellow_sticky)

GSK-IDRx
$1.15B cash buyout (incl $150M regulatory milestone)
MoA: KIT
Stage: phase-1b
Reference: #msg-175655362

GILD-Leo
Global collaboration: $250M up-front; $1.7B biobucks
MoA: STAT6
Stage: preclinical
Reference: #msg-175651641

👍️ 3

alertmeipp 1 day ago

Yes, disappointing, although I can see ENTA is trying to go UP today but the selling pressure persists. It is weird. I don’t even know which entities have so many shares readily available to sell after so much selling already

👍️0

dewophile 1 day ago

I miss the days when deals like this, JNJ etc would be good for a nice upward push in biotechs
The GILD deal on top of these right in ENTA's space would have been good for 10% plus - shows you how bad sentiment is right now

👍️ 3

DewDiligence 1 day ago

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

• IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability…

Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. IDRX-42 is in phase-1/1b clinical development.

👍 1 👍️ 3

alertmeipp 2 days ago

Total is now 1.198 million shares. Pretty significant.

Top Institutional Holders
Farallon Capital Management LLC 2.11M Sep 30, 2024 9.95% 10,731,053
Vanguard Group Inc 1.98M Sep 30, 2024 9.35% 10,087,698
Blackrock Inc. 1.9M Sep 30, 2024 8.97% 9,672,644
Krensavage Asset Management, LLC 1.5M Sep 30, 2024 7.07% 7,625,196
This board
Morgan Stanley 1.1M Sep 30, 2024 5.20% 5,613,516

👍 4

biotech2020 2 days ago

108k shares here

👍️ 2

alertmeipp 3 days ago

Wow, I assume Leo’s stat6 program is much further along compared to ENTAs’? But it can’t be that far as they are still pre-clinical?

Why would Gilead pay so much upfront for it? I think dewophile quoted another similar deal, $150mm iirc, and also preclinical.

Maybe the next partnership news would be ENTA but on immunology instead of RSV. ;)

👍️ 2

alertmeipp 3 days ago

Total is now 1.09mm shares - slightly over 7 percent of the public float.

If we were a fund, we would be the 5th largest holder, on par with MS. We should have a say on ENTA future direction ;)

👍️ 2

vinmantoo 3 days ago

Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.

Wow, with the numbers Alertmeipp has now gathered that means ~1 million shares from this people who use this board. I am just an Academic scientist who is relatively poor so my shares would be a rounding error so are not worth mentioning. You money bags guys can buy me a drink if ENTA does come back and hits big! 😁 🥂

After the long ENTA decline it represents ~10% or

👍️ 1

DewDiligence 3 days ago

GILD, Leo Pharma ink STAT6 collaboration:

https://www.businesswire.com/news/home/20250111983856/en Gilead Sciences…and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

…Targeting STAT6 has shown potential preclinically to treat a broad population of patients and provide an oral alternative to those currently treated with injectable biologics.

Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.

…Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 program. LEO Pharma will have the option to potentially co-commercialize oral programs for dermatology outside the United States. LEO Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology.

LEO Pharma is eligible to receive up to $1.7 billion in total payments, including an upfront payment of $250 million. In addition, LEO Pharma may also receive tiered royalties ranging from high single-digit to mid-teens on sales of oral STAT6 products. Gilead may receive tiered royalties ranging from high single-digit to mid-teens on sales of topical STAT6 products.

👍️ 6

DewDiligence 3 days ago

Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.

alertmeipp 3 days ago

Total now 720k - 4.67% of the public float (15.44mm) just from a few of us.
Interesting
(720370 shares).

👍️0

alertmeipp 3 days ago

considering more at this level.

The risk reward has been great since it traded below net cash value.. just couldn't imagine it can go this low.

👍 1

alertmeipp 3 days ago

>> down over $200k

Nice job actually, I would love to trade your cost basis with you any time. ;)

33,200 shares and considering more at this level.

👍️ 2

LS89 3 days ago

129,770 and down over $200k

👍️ 2

alertmeipp 4 days ago

Enta is ripe for an activist investor

Won't be surprised at all if it happens. Could be easy money as long as they can ensure the company be rational on its RSV program.

👍️0

alertmeipp 4 days ago

Thanks, we have 555k total now.

alertmeipp 4 days ago

FWIW - Another 250k plus traded after hours

👍️0

alertmeipp 4 days ago

I'm over 100k, so that's 2% of the float already.
Total is over 435k already.

👍️ 1

floblu14 4 days ago

FLO = 100K

BABY FLO = .01

alertmeipp 4 days ago

I wonder how many shares this board own in total. Is there a way to do a tally in this board?

👍️0

alertmeipp 4 days ago

Some insider buys would be appreciated

👍️ 2

biotech_researcher 4 days ago

Liquidation phase..

👍️0

dewophile 4 days ago

Enta is ripe for an activist investor

👍️ 3

vinmantoo 4 days ago

This is officially the ENTA theme song. "How low can you go"!

👍 1 👍️ 1 😂 2

wags23 4 days ago

Why would you want bad news?

👍️0

biotech_researcher 4 days ago

The JPM conference can't come soon enough for ENTA..

👍️ 1

alertmeipp 5 days ago

Same. I guess that's the fun of small biotech investing. Out sized moves are the norm on both sides. Just hope we have some real news that would justify the 70% down move from $13 few short months ago.

👍️ 1

alertmeipp 5 days ago

No doubt, got lucky there. Hopefully here as well.

👍️0

dewophile 5 days ago

You lucked out on RVNC most lost money there - that is an example of a distressed buyout for sure. I have one example where I lost money despite a buyout and that was ZGEN. Sure I made back some paper losses, but net net was a loss. Can't win them all

👍️ 2

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Enanta Pharmaceuticals Inc (ENTA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ENTA News

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ENTA Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Enanta Pharmaceuticals Inc (ENTA) News

Enanta Pharmaceuticals Inc (ENTA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ENTA News

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ENTA Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free